ZENAPAX Side Effects

6921004-0 | Argininosuccinate Synthetase Deficiency, Graft Dysfunction
on Aug 03, 2010 Female patient from UNITED KINGDOM , child 8 years of age, weighting 64.60 lb, was diagnosed with liver transplant rejection and was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: argininosuccinate synthetase deficiency, graft dysfunction. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), AMBISOME (View Ambisome Review and Ambisome Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), NYSTATIN (View Nystatin Review and Nystatin Label ).

6916628-0 | Argininosuccinate Synthetase Deficiency, Graft Dysfunction
Patient was taking Zenapax (View Usage). Patient had the following side effects: argininosuccinate synthetase deficiency, graft dysfunction on Aug 03, 2010 from UNITED KINGDOM Additional patient health information: Female patient , child 8 years of age, weighting 64.60 lb, was diagnosed with liver transplant rejection and. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), AMBISOME (View Ambisome Review and Ambisome Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), NYSTATIN (View Nystatin Review and Nystatin Label ).

6822664-5 | Graft Dysfunction, Ill-defined Disorder
Adverse event was reported on Jul 02, 2010 by a Female patient taking Zenapax (View Usage) (Dosage: ) was diagnosed with liver transplant rejection and. Location: UNITED KINGDOM , child 8 years of age, weighting 64.60 lb, After Zenapax was administered, patient had the following side effects: graft dysfunction, ill-defined disorder. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), AMBISOME (View Ambisome Review and Ambisome Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), NYSTATIN (View Nystatin Review and Nystatin Label ).

6751420-1 | Bone Marrow Failure
on Aug 13, 2003 Male patient from BRAZIL , weighting 145.5 lb, was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow failure. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ). Patient was hospitalized.


6638881-3 | Myelodysplastic Syndrome
on Mar 16, 2010 Male patient from UNITED STATES , 68 years of age, weighting 204.8 lb, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Zenapax (View Usage). Patient had the following side effects: myelodysplastic syndrome. Zenapax dosage: Zenpax 5 Mg Iv Drip Yttrium 90 10-15mci Iv Drip.

6392036-9 | Acute Graft Versus Host Disease In Skin, Bone Marrow Failure, Diarrhoea
Patient was taking Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: acute graft versus host disease in skin, bone marrow failure, diarrhoea on Sep 29, 2009 from UNITED STATES Additional patient health information: Female patient , 18 years of age, . Zenapax dosage: Received Two Doses On 26 And 28 Dec 2008. During the same period patient was treated with PENTOSTATIN (View Pentostatin Review and Pentostatin Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6187969-2 | Transplant Rejection
Adverse event was reported on May 04, 2009 by a Male patient taking Zenapax (View Usage) (Dosage: Form: Infusion.) . Location: INDIA , 40 years of age, weighting 163.1 lb, Patient experienced the following unwanted or unexpected effects: transplant rejection. During the same period patient was treated with TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), MMF (View Mmf Review and Mmf Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6139872-1 | Dyspnoea, Influenza Like Illness, Lung Disorder
on Mar 31, 2009 Female patient from UNITED STATES , weighting 178.4 lb, was treated with Zenapax (View Usage). Patient had the following side effects: dyspnoea, influenza like illness, lung disorder. Zenapax dosage: 5mg/ml Vial 70 Mg X1. During the same period patient was treated with BECONASE (BECLOMETHASONE DIPROPIONATE NASAL) (View Beconase (beclomethasone Dipropionate Nasal) Review and Beconase (beclomethasone Dipropionate Nasal) Label ), CONCERTA (METHYLPHENIDATE EXTENDED RELEASE) (View Concerta (methylphenidate Extended Release) Review and Concerta (methylphenidate Extended Release) Label ), DOXAZOSIN MESYLATE (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), HYDROCORTISONE 2.5% (View Hydrocortisone 2.5% Review and Hydrocortisone 2.5% Label ), HYDROXYZINE HCL (View Hydroxyzine Hcl Review and Hydroxyzine Hcl Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MIRAPEX (View Mirapex Review and Mirapex Label ), MOTRIN (View Motrin Review and Motrin Label ). Patient was hospitalized and became disabled.

6103770-X | Disseminated Intravascular Coagulation, Sepsis
on Feb 21, 2009 Female patient from IRAN (ISLAMIC REPUBLIC OF) , 35 years of age, was treated with Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: disseminated intravascular coagulation, sepsis (What is sepsis?). Zenapax dosage: . During the same period patient was treated with CELLCEPT (Recived On Day 1st And 2nd After Transplantation) (View Cellcept Review and Cellcept Label ), CYCLOSPORINE (On The 1st Day After Transplantation) (View Cyclosporine Review and Cyclosporine Label ).

5835732-1 | Sinus Bradycardia
Patient was taking Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: sinus bradycardia on Jul 28, 2008 from UNITED STATES Additional patient health information: Male patient , 32 years of age, was diagnosed with liver transplant (What is liver transplant?) and. Zenapax dosage: . During the same period patient was treated with SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ), VALGANCICLOVIR HCL (View Valganciclovir Hcl Review and Valganciclovir Hcl Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CLOTRIMAZOLE (View Clotrimazole Review and Clotrimazole Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), SEVELAMER (View Sevelamer Review and Sevelamer Label ), URSODIOL (View Ursodiol Review and Ursodiol Label ). Patient was hospitalized.

5816584-2 | Breast Cancer, Ovarian Cyst Ruptured
Adverse event was reported on Jul 07, 2008 by a Female patient taking Zenapax (View Usage) (Dosage: Immediately Before Transplantation) . Location: UNITED STATES , 64 years of age, Patient had the following side effects: breast cancer (What is breast cancer?), ovarian cyst ruptured. During the same period patient was treated with SIROLIMUS (Loading Dose Pre-transplant) (View Sirolimus Review and Sirolimus Label ), TACROLIMUS (Immediately Before Transplantation) (View Tacrolimus Review and Tacrolimus Label ), HEPARIN (Total Dose 5000 Units Per Transplant.) (View Heparin Review and Heparin Label ), ENOXAPARIN SODIUM (1 Week Post-transplant) (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ). Patient was hospitalized.

5746212-6 | Acute Pulmonary Oedema, Acute Respiratory Distress Syndrome, Toxoplasmosis
on May 16, 2008 Male patient from FRANCE , weighting 94.80 lb, was diagnosed with graft versus host disease, prophylaxis against transplant rejection and was treated with Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: acute pulmonary oedema, acute respiratory distress syndrome, toxoplasmosis. Zenapax dosage: Form: Injectable Solution.. During the same period patient was treated with CELLCEPT (Form: Injectable Solution.) (View Cellcept Review and Cellcept Label ), SANDIMMUNE (Form: Injectable Solution.) (View Sandimmune Review and Sandimmune Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), LOXEN (View Loxen Review and Loxen Label ), PLITICAN (View Plitican Review and Plitican Label ), VANCOCIN HCL (View Vancocin Hcl Review and Vancocin Hcl Label ), FORTUM (View Fortum Review and Fortum Label ), CANCIDAS (View Cancidas Review and Cancidas Label ).

5739228-7 | Acute Pulmonary Oedema, Acute Respiratory Distress Syndrome, Toxoplasmosis
on Apr 30, 2008 Male patient from FRANCE , weighting 94.80 lb, was diagnosed with graft versus host disease, bone marrow transplant (What is bone marrow transplant?) and was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: acute pulmonary oedema, acute respiratory distress syndrome, toxoplasmosis. Zenapax dosage: . During the same period patient was treated with CELLCEPT (View Cellcept Review and Cellcept Label ), SANDIMMUNE (View Sandimmune Review and Sandimmune Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), LOXEN (View Loxen Review and Loxen Label ), PLITICAN (View Plitican Review and Plitican Label ), VANCOCIN HCL (View Vancocin Hcl Review and Vancocin Hcl Label ).

5735018-X | Acute Pulmonary Oedema, Acute Respiratory Distress Syndrome, Toxoplasmosis
Patient was taking Zenapax (View Usage). Patient had the following side effects: acute pulmonary oedema, acute respiratory distress syndrome, toxoplasmosis on May 06, 2008 from FRANCE Additional patient health information: Male patient , weighting 94.80 lb, was diagnosed with graft versus host disease, bone marrow transplant (What is bone marrow transplant?) and. Zenapax dosage: . During the same period patient was treated with CELLCEPT (View Cellcept Review and Cellcept Label ), SANDIMMUNE (View Sandimmune Review and Sandimmune Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), LOXEN (View Loxen Review and Loxen Label ), PLITICAN (View Plitican Review and Plitican Label ), VANCOCIN HCL (View Vancocin Hcl Review and Vancocin Hcl Label ).

5729133-4 | Acute Pulmonary Oedema, Acute Respiratory Distress Syndrome, Toxoplasmosis
Adverse event was reported on Apr 30, 2008 by a Male patient taking Zenapax (View Usage) (Dosage: ) was diagnosed with prophylaxis against transplant rejection and. Location: FRANCE , weighting 94.80 lb, After Zenapax was administered, patient had the following side effects: acute pulmonary oedema, acute respiratory distress syndrome, toxoplasmosis. During the same period patient was treated with CELLCEPT (View Cellcept Review and Cellcept Label ), SANDIMMUNE (View Sandimmune Review and Sandimmune Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), LOXEN (View Loxen Review and Loxen Label ), PLITICAN (View Plitican Review and Plitican Label ), VANCOCIN HCL (View Vancocin Hcl Review and Vancocin Hcl Label ).

5699668-1 | Acute Respiratory Distress Syndrome, Cough, Dyspnoea, Graft Versus Host Disease, Multi-organ Failure, Pulmonary Oedema, Toxoplasmosis
on Apr 04, 2008 Male patient from FRANCE , child 11 years of age, weighting 94.80 lb, was diagnosed with bone marrow transplant (What is bone marrow transplant?) and was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome, cough, dyspnoea, graft versus host disease, multi-organ failure, pulmonary oedema, toxoplasmosis. Zenapax dosage: Unk, Once/single. During the same period patient was treated with CELLCEPT (650 Mg, Tid) (View Cellcept Review and Cellcept Label ), SOLU MEDROL (50 Mg, Qid) (View Solu-medrol Review and Solu-medrol Label ), LOXEN (View Loxen Review and Loxen Label ), PLITICAN (View Plitican Review and Plitican Label ), VANCOMYCIN HCL (View Vancomycin Hcl Review and Vancomycin Hcl Label ), FORTUM /UNK/ (View Fortum /unk/ Review and Fortum /unk/ Label ), CANCIDAS (View Cancidas Review and Cancidas Label ), ZOVIRAX (View Zovirax Review and Zovirax Label ).

5534274-0 | Abnormal Behaviour, Convulsion
on Nov 26, 2007 Male patient from UNITED STATES , 53 years of age, was treated with Zenapax (View Usage). Patient had the following side effects: abnormal behaviour, convulsion. Zenapax dosage: . During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CLONIDINE (View Clonidine Review and Clonidine Label ), DOCUSATE (View Docusate Review and Docusate Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), HEPARIN (View Heparin Review and Heparin Label ), KEPPRA (View Keppra Review and Keppra Label ), CELLCEPT (View Cellcept Review and Cellcept Label ). Patient was hospitalized.

5499713-2 | Anaemia, Renal Tubular Necrosis, Thrombocytopenia
Patient was taking Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: anaemia, renal tubular necrosis, thrombocytopenia on Oct 18, 2007 from INDIA Additional patient health information: Female patient , child 11 years of age, weighting 66.14 lb, was diagnosed with prophylaxis against transplant rejection and. Zenapax dosage: . During the same period patient was treated with STEROID NOS (View Steroid Nos Review and Steroid Nos Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

5483737-5 | Condition Aggravated, Conjunctival Hyperaemia, Conjunctival Oedema, Dysphagia, No Therapeutic Response, Perivascular Dermatitis, Photosensitivity Reaction, Rash, Rash Macular
Adverse event was reported on Oct 09, 2007 by a Male patient taking Zenapax (View Usage) (Dosage: 708mg (8mg/kg) Every 3 Weeks Iv) was diagnosed with human t-cell lymphotropic virus infection and. Location: UNITED STATES , weighting 183.0 lb, Patient experienced the following unwanted or unexpected effects: condition aggravated, conjunctival hyperaemia, conjunctival oedema, dysphagia, no therapeutic response, perivascular dermatitis, photosensitivity reaction, rash (What is rash?), rash macular. During the same period patient was treated with LORTADINE (View Lortadine Review and Lortadine Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), BENADRYL (View Benadryl Review and Benadryl Label ), PEPCID (View Pepcid Review and Pepcid Label ), KETOCONAZOLE (View Ketoconazole Review and Ketoconazole Label ), KERI LOTION (View Keri Lotion Review and Keri Lotion Label ), AVEENO OATMEAL BATH (View Aveeno Oatmeal Bath Review and Aveeno Oatmeal Bath Label ).

5303198-6 | Anaphylactic Shock
on Apr 12, 2007 Male patient from INDIA , 50 years of age, was diagnosed with tuberculosis (What is tuberculosis?), renal transplant and was treated with Zenapax (View Usage). Patient had the following side effects: anaphylactic shock. Zenapax dosage: Dose Infused Over 30 Mins. During the same period patient was treated with RIFAMPICIN (View Rifampicin Review and Rifampicin Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), ETHAMBUTOL HYDROCHLORIDE (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

5300916-8 | Anaphylactic Shock
on Apr 09, 2007 Male patient from INDIA , 50 years of age, was diagnosed with tuberculosis (What is tuberculosis?) and was treated with Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: anaphylactic shock. Zenapax dosage: . During the same period patient was treated with RIFAMPICIN (View Rifampicin Review and Rifampicin Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), ETHAMBUTOL HYDROCHLORIDE (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ).

5288688-7 | Breast Cancer
Patient was taking Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: breast cancer (What is breast cancer?) on Mar 27, 2007 from UNITED STATES Additional patient health information: Female patient , 38 years of age, weighting 138.9 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Zenapax dosage: Received Scheduled 7th And Last Dose On 29 December 2005.. During the same period patient was treated with AMBIEN (View Ambien Review and Ambien Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), REBIF (View Rebif Review and Rebif Label ), QUININE (View Quinine Review and Quinine Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), ZANAFLEX (View Zanaflex Review and Zanaflex Label ), INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ).

5288260-9 | Anastomotic Complication, Gastroenteritis Viral, Haematoma, Renal Failure Acute, Urinary Tract Infection
Adverse event was reported on Mar 29, 2007 by a Male patient taking Zenapax (View Usage) (Dosage: ) . Location: CANADA , 53 years of age, weighting 162.7 lb, Patient had the following side effects: anastomotic complication, gastroenteritis viral, haematoma, renal failure acute, urinary tract infection (What is urinary tract infection?). During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (Frequency Reported As Die.) (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

5286830-5 | Chest Pain, Cytomegalovirus Infection, Dyspnoea, Fatigue
on Mar 23, 2007 Male patient from FRANCE , 60 years of age, was treated with Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: chest pain (What is chest pain?), cytomegalovirus infection (What is cytomegalovirus infection?), dyspnoea, fatigue. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), METHYLPREDNISOLONE 16MG TAB (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ). Patient was hospitalized.

5286829-9 | Abdominal Distension, Abdominal Pain, Atelectasis, Cardiovascular Disorder, Gastrointestinal Haemorrhage, Haemoglobin Decreased, Hepatic Haematoma, Hypopnoea, Platelet Count Decreased
on Mar 29, 2007 Male patient from SWEDEN , 59 years of age, was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal distension, abdominal pain (What is abdominal pain?), atelectasis, cardiovascular disorder, gastrointestinal haemorrhage, haemoglobin decreased, hepatic haematoma, hypopnoea, platelet count decreased. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHYLPREDNISOLONE 16MG TAB (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ).

5284619-4 | Septic Shock
Patient was taking Zenapax (View Usage). Patient had the following side effects: septic shock on Mar 23, 2007 from FRANCE Additional patient health information: Male patient , 34 years of age, was diagnosed with prophylaxis and. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (Dose Adjusted To Reach Pre-defined Target Levels) (View Tacrolimus Review and Tacrolimus Label ), METHYLPREDNISOLONE 16MG TAB (Dose Tapered According To Local Protocol) (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ), PREDNISONE (Dose Tapered According To Local Protocol) (View Prednisone Review and Prednisone Label ), PIPERILLINE (View Piperilline Review and Piperilline Label ). Patient was hospitalized.

5280219-0 | Sepsis
Adverse event was reported on Mar 23, 2007 by a Female patient taking Zenapax (View Usage) (Dosage: ) . Location: NETHERLANDS , 58 years of age, After Zenapax was administered, patient had the following side effects: sepsis (What is sepsis?). During the same period patient was treated with FK 506 (View Fk 506 Review and Fk 506 Label ), HYDROCORTISON (View Hydrocortison Review and Hydrocortison Label ).

5273848-1 | Cardio-respiratory Arrest, Interstitial Lung Disease, Meningitis, Pyrexia
on Mar 13, 2007 Female patient from UNITED STATES , 33 years of age, weighting 242.5 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest, interstitial lung disease, meningitis (What is meningitis?), pyrexia. Zenapax dosage: . During the same period patient was treated with INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ), CLORAZEPATE (View Clorazepate Review and Clorazepate Label ), MICRODIOL (View Microdiol Review and Microdiol Label ), ORLISTAT (View Orlistat Review and Orlistat Label ). Patient was hospitalized.

5269643-X | Acute Respiratory Distress Syndrome, Pneumothorax
on Nov 10, 2006 Male patient from FRANCE , 43 years of age, was treated with Zenapax (View Usage). Patient had the following side effects: acute respiratory distress syndrome, pneumothorax. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (Dose Adjusted To Reach Predefined Target Level) (View Tacrolimus Review and Tacrolimus Label ), METHYLPREDNISOLONE 16MG TAB (Tapered According To Local Protocol) (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ), PREDNISONE (Tapered According To Local Protocol) (View Prednisone Review and Prednisone Label ), GANCICLOVIR (View Ganciclovir Review and Ganciclovir Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

5266308-5 | Back Pain, Chills, Hyperhidrosis, Malaise, Nausea, Pollakiuria, Pyelonephritis
Patient was taking Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: back pain (What is back pain?), chills, hyperhidrosis, malaise, nausea (What is nausea?), pollakiuria, pyelonephritis on Mar 06, 2007 from AUSTRALIA Additional patient health information: Female patient , 43 years of age, . Zenapax dosage: . During the same period patient was treated with PROGRAF (View Prograf Review and Prograf Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

5266298-5 | Cardio-respiratory Arrest, Interstitial Lung Disease, Meningitis, Pyrexia
Adverse event was reported on Mar 01, 2007 by a Female patient taking Zenapax (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 33 years of age, weighting 242.5 lb, Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest, interstitial lung disease, meningitis (What is meningitis?), pyrexia. During the same period patient was treated with INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ), CLORAZEPATE (View Clorazepate Review and Clorazepate Label ), MICRODIOL (View Microdiol Review and Microdiol Label ), ORLISTAT (View Orlistat Review and Orlistat Label ). Patient was hospitalized.

5263593-0 | Cardio-respiratory Arrest, Interstitial Lung Disease, Meningitis, Pyrexia
on Mar 01, 2007 Female patient from UNITED STATES , 33 years of age, weighting 242.5 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Zenapax (View Usage). Patient had the following side effects: cardio-respiratory arrest, interstitial lung disease, meningitis (What is meningitis?), pyrexia. Zenapax dosage: The Last Dose Of Daclizumab Was Administered On 09/08/06 Which Signified The Completion Of The Pres+. During the same period patient was treated with INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ), CLORAZEPATE (View Clorazepate Review and Clorazepate Label ), MICRODIOL (View Microdiol Review and Microdiol Label ), ORLISTAT (View Orlistat Review and Orlistat Label ). Patient was hospitalized.

5263592-9 | Anxiety, Back Pain, Blood Potassium Decreased, Clostridium Difficile Toxin Test Positive, Constipation, Dehydration, Dental Caries, Depressed Level Of Consciousness, Ear Pain
on Mar 06, 2007 Female patient from UNITED STATES , 50 years of age, weighting 137.8 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: anxiety (What is anxiety?), back pain (What is back pain?), blood potassium decreased, clostridium difficile toxin test positive, constipation (What is constipation?), dehydration, dental caries, depressed level of consciousness, ear pain. Zenapax dosage: . During the same period patient was treated with INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ), ALERTEC (View Alertec Review and Alertec Label ), OMEGA 3 TRIGLYCERIDES (Reported As Omega 3.) (View Omega-3 Triglycerides Review and Omega-3 Triglycerides Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), VITAMIN B 12 (View Vitamin B-12 Review and Vitamin B-12 Label ), MSM JOINT FORMULA (Reported As Msm.) (View Msm Joint Formula Review and Msm Joint Formula Label ), DOCUSATE SODIUM (View Docusate Sodium Review and Docusate Sodium Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ). Patient was hospitalized.

5263589-9 | Rectocele
Patient was taking Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: rectocele on Mar 06, 2007 from UNITED STATES Additional patient health information: Female patient , 50 years of age, weighting 137.8 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Zenapax dosage: . During the same period patient was treated with COLACE (View Colace Review and Colace Label ), AMITRIPTYLINE HCL (View Amitriptyline Hcl Review and Amitriptyline Hcl Label ), ZYPREXA (View Zyprexa Review and Zyprexa Label ), LIPITOR (View Lipitor Review and Lipitor Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), LYRICA (View Lyrica Review and Lyrica Label ). Patient was hospitalized.

5258643-1 | Renal Failure Acute
Adverse event was reported on Feb 28, 2007 by a Male patient taking Zenapax (View Usage) (Dosage: ) was diagnosed with liver transplant (What is liver transplant?) and. Location: NETHERLANDS , 59 years of age, Patient had the following side effects: renal failure acute. During the same period patient was treated with FK506 (View Fk506 Review and Fk506 Label ). Patient was hospitalized.

5257159-6 | Hyperkalaemia
on Feb 28, 2007 Male patient from NETHERLANDS , 47 years of age, was diagnosed with liver transplant (What is liver transplant?) and was treated with Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: hyperkalaemia. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ).

5254156-1 | Acute Respiratory Distress Syndrome
on Feb 19, 2007 Female patient from UNITED KINGDOM , child 12 years of age, was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome. Zenapax dosage: .

5253311-4 | Intervertebral Discitis, Osteopenia
Patient was taking Zenapax (View Usage). Patient had the following side effects: intervertebral discitis, osteopenia on Feb 21, 2007 from BELGIUM Additional patient health information: Male patient , 61 years of age, . Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

5247805-5 | Nuclear Magnetic Resonance Imaging Abnormal
Adverse event was reported on Feb 16, 2007 by a Female patient taking Zenapax (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 38 years of age, weighting 138.9 lb, After Zenapax was administered, patient had the following side effects: nuclear magnetic resonance imaging abnormal. During the same period patient was treated with AMBIEN (View Ambien Review and Ambien Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), LIDOCAINE (View Lidocaine Review and Lidocaine Label ), INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ), LYRICA (View Lyrica Review and Lyrica Label ).

5245202-X | Acute Respiratory Distress Syndrome, Pleural Effusion, Pulmonary Oedema
on Feb 14, 2007 Female patient from NETHERLANDS , child 12 years of age, was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome, pleural effusion, pulmonary oedema. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), CEFOTAXIME (View Cefotaxime Review and Cefotaxime Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ), METHYLPREDNISOLONE 16MG TAB (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ). Patient was hospitalized.

5244117-0 | Cardio-respiratory Arrest, Interstitial Lung Disease, Meningitis, Pyrexia
on Feb 10, 2007 Female patient from UNITED STATES , 33 years of age, weighting 242.5 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Zenapax (View Usage). Patient had the following side effects: cardio-respiratory arrest, interstitial lung disease, meningitis (What is meningitis?), pyrexia. Zenapax dosage: The Last Dose Of Daclizumab Was Administered On 09/08/06 Which Signified The Completion Of The Pres+. During the same period patient was treated with INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ), CLORAZEPATE (View Clorazepate Review and Clorazepate Label ), MICRODIOL (View Microdiol Review and Microdiol Label ), ORLISTAT (View Orlistat Review and Orlistat Label ). Patient was hospitalized.

5242653-4 | Acute Respiratory Distress Syndrome
Patient was taking Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: acute respiratory distress syndrome on Feb 14, 2007 from NETHERLANDS Additional patient health information: Female patient , child 12 years of age, . Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), CEFOTAXIME (View Cefotaxime Review and Cefotaxime Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ), METHYLPREDNISOLONE 16MG TAB (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ). Patient was hospitalized.

5238383-5 | Renal Failure
Adverse event was reported on Feb 07, 2007 by a Female patient taking Zenapax (View Usage) (Dosage: ) . Location: NETHERLANDS , 60 years of age, Patient experienced the following unwanted or unexpected effects: renal failure. During the same period patient was treated with FK506 (View Fk506 Review and Fk506 Label ). Patient was hospitalized.

5237689-3 | Acute Respiratory Distress Syndrome
on Feb 05, 2007 Female patient from UNITED KINGDOM , child 12 years of age, was treated with Zenapax (View Usage). Patient had the following side effects: acute respiratory distress syndrome. Zenapax dosage: .

5235996-1 | Interstitial Lung Disease, Meningitis, Meningitis Aseptic
on Feb 01, 2007 Female patient from UNITED STATES , 33 years of age, weighting 242.5 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: interstitial lung disease, meningitis (What is meningitis?), meningitis aseptic. Zenapax dosage: The Last Dose Of Daclizumab Was Administered On 09/08/06 Which Signified The Completion Of The Pres+. During the same period patient was treated with INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ), CLORAZEPATE (View Clorazepate Review and Clorazepate Label ), MICRODIOL (View Microdiol Review and Microdiol Label ), ORLISTAT (View Orlistat Review and Orlistat Label ). Patient was hospitalized.

5232585-X | Bacterial Infection, Dehydration, Diarrhoea, Flank Pain, Gastroenteritis, Transplant Rejection
Patient was taking Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: bacterial infection (What is bacterial infection?), dehydration, diarrhoea, flank pain, gastroenteritis (What is gastroenteritis?), transplant rejection on Jan 25, 2007 from CANADA Additional patient health information: Male patient , 53 years of age, . Zenapax dosage: First Dose.. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), PANTOPRAZOLE SODIUM (Dosage Form Reported As Ent (ears Nose Throat).) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), LIPITOR (View Lipitor Review and Lipitor Label ), ARANESP (View Aranesp Review and Aranesp Label ), NORVASC (View Norvasc Review and Norvasc Label ), VALCYTE (View Valcyte Review and Valcyte Label ).

5231154-5 | Staphylococcal Sepsis
Adverse event was reported on Jan 28, 2007 by a Male patient taking Zenapax (View Usage) (Dosage: ) . Location: FRANCE , 63 years of age, weighting 180.8 lb, Patient had the following side effects: staphylococcal sepsis. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), SOLU MEDROL (Reported As Solumedrol Methylprednisolone.) (View Solu-medrol Review and Solu-medrol Label ), NEORAL (View Neoral Review and Neoral Label ), HEPARIN (View Heparin Review and Heparin Label ), INSULIN (View Insulin Review and Insulin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

5228850-2 | Human Herpesvirus 8 Infection
on Jan 30, 2007 Male patient from FRANCE , 44 years of age, was treated with Zenapax (View Usage). After Zenapax was administered, patient had the following side effects: human herpesvirus 8 infection. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (Adjusted To Reach Predefined Target Levels) (View Tacrolimus Review and Tacrolimus Label ).

5228495-4 | Human Herpesvirus 8 Infection
on Jan 30, 2007 Male patient from FRANCE , 44 years of age, was treated with Zenapax (View Usage). Patient experienced the following unwanted or unexpected effects: human herpesvirus 8 infection. Zenapax dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (Adjusted To Reach Predefined Target Levels) (View Tacrolimus Review and Tacrolimus Label ).

5227161-9 | Klebsiella Infection
Patient was taking Zenapax (View Usage). Patient had the following side effects: klebsiella infection on Jan 24, 2007 from FRANCE Additional patient health information: Male patient , 53 years of age, . Zenapax dosage: 2 Mg/kg Dose According To Protocol.. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.